Scripps Research expands drug repurposing efforts for COVID-19

By The Science Advisory Board staff writers

Scripps Research has pivoted its drug repurposing collection ReFRAME to find antiviral compounds effective against the novel coronavirus.

Researchers from Scripps' drug development division Calibr will work with scientists from around the world to look for compounds from individual drugs or drug combinations that could treat patients with COVID-19. It is part of an accelerator launched by the Bill & Melinda Gates Foundation to develop COVID‑19 therapeutics.

Scripps Research
Scripps Research's ReFRAME drug repurposing collection. Image courtesy of Scripps Research.

ReFrame's collection includes 14,000 compounds, including medications already repurposed for disease treatment. Calibr created the collection in 2018 to address tropical diseases and other unmet medical needs.

Copyright © 2020

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?